Last reviewed · How we verify
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This phase II trial studies the effects of venetoxlax in combination with decitabine and cedazuridine in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as venetoclax and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cedazuridine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoxlax in combination with decitabine and cedazuridine may help to control acute myeloid leukemia.
Details
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 20 |
| Start date | Wed Sep 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun May 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Recurrent Acute Biphenotypic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Biphenotypic Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
- Decitabine and Cedazuridine
- Venetoclax
Countries
United States